Literature DB >> 11835455

Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.

Charles H Adler1, Stewart A Factor, Mitchell Brin, Kapil D Sethi.   

Abstract

Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period. Copyright 2002 Movement Disorder Society.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11835455     DOI： 10.1002/mds.10001

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

2.  Botulinum toxin in the management of dystonia.

Authors:  Omar D Cardona-Garcia; Donald S Higgins; Eric S Molho
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

3.  [Muscle afferent block in the treatment of oromandibular dystonia. Difference in effect between masticatory and lingual muscles].

Authors:  K Yoshida
Journal:  Nervenarzt       Date:  2003-05-13       Impact factor: 1.214

4.  Management of Oromandibular Dystonia: A Case Report and Literature Update.

Authors:  Suma Gn; Adrita Nag
Journal:  Case Rep Dent       Date:  2017-06-19

5.  Oromandibular Dystonia: A Clinical Examination of 2,020 Cases.

Authors:  Laura M Scorr; Stewart A Factor; Sahyli Perez Parra; Rachel Kaye; Randal C Paniello; Scott A Norris; Joel S Perlmutter; Tobias Bäumer; Tatiana Usnich; Brian D Berman; Marie Mailly; Emmanuel Roze; Marie Vidailhet; Joseph Jankovic; Mark S LeDoux; Richard Barbano; Florence C F Chang; Victor S C Fung; Sarah Pirio Richardson; Andrew Blitzer; H A Jinnah
Journal:  Front Neurol       Date:  2021-09-16       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.